Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | CCR7 | P32248 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14834356 | 0.86 | CCR6 (0.59) | CCR6NPC1RAB9ACYP3A4CYP2D6 | |
| SCHEMBL14814958 | 0.83 | CCR6 (0.46) | CCR6NPC1RAB9ACYP3A4CYP2D6 | |
| SCHEMBL26120478 | 0.83 | CCNK (0.47) | HCRTR1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL17729502 | 0.82 | SYK (0.50) | CCR6CYP3A4CYP2D6CYP2C9HSD11B1 | |
| SCHEMBL21722966 | 0.80 | EPHX2 (0.46) | NPC1RAB9AEPHX2 | |
| SCHEMBL15739645 | 0.79 | CCR6 (0.61) | CCR6HCRTR1DPP4NPY5RCCR7 | |
| SCHEMBL15739705 | 0.76 | HCRTR1 (0.55) | CCR6HCRTR1DPP4CCR7 | |
| SCHEMBL18607634 | 0.76 | CCR6 (0.55) | CCR6HCRTR1DPP4CCR7 | |
| SCHEMBL21853973 | 0.75 | CCNK (0.53) | CCR6CYP3A4CYP2D6CYP2C9HSD11B1 | |
| SCHEMBL17741141 | 0.75 | CCR6 (0.48) | CCR6NPC1RAB9AHCRTR1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | disclosed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | disclosed |
| EP-3215500-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | Dart NeuroScience (Cayman) Ltd. (KY) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073420-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | CCR6 2698/4885NPC1 217/4885RAB9A 2184/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | CCR6 2698/4885NPC1 217/4885RAB9A 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.